Blog
RSS FeedPosted by Michael Wonder on 19 Sep 2016
Talimogene laherparepvec in melanoma: additional clinical benefit not proven
15 September 2016 - Drug manufacturer dossier contained no data suitable for the assessment. ...
Posted by Michael Wonder on 17 Sep 2016
Selexipag in pulmonary arterial hypertension: additional clinical benefit is not proven
16 September 2016 - Limited comparator therapy and division of population inadequate/the only study compared the medicine with placebo. ...
Posted by Michael Wonder on 15 Sep 2016
Ticagrelor for prevention after myocardial infarction: added benefit called into question by data subsequently submitted
15 September 2016 - Greater consistency and certainty of conclusions of the results regarding harmful aspects. ...
Posted by Michael Wonder on 07 Sep 2016
Eribulin in liposarcoma: added benefit not proven
1 September 2016 - Neither results from a study of direct comparison nor from an indirect comparison were suitable. ...
Posted by Michael Wonder on 05 Sep 2016
Eisai bewildered as Germany's IQWIG fails to recognise additional benefit of Halaven (eribulin mesylate) in the treatment of advanced liposarcoma
4 September 2016 - Assessment ignores unprecedented overall survival benefit for eribulin in advanced liposarcoma. ...
Posted by Michael Wonder on 01 Sep 2016
Elotuzumab in multiple myeloma: additional clinical benefit is not proven
1 September 2016 - The only study available was unsuitable for the benefit assessment. ...
Posted by Michael Wonder on 15 Aug 2016
Emtricitabine with tenofovir alafenamide fumarate in HIV infection: additional benefits not covered
15 August 2016 - Deviation from the appropriate comparator therapy/higher loss for certain patients. ...
Posted by Michael Wonder on 06 Aug 2016
Brivaracetam in epilepsy: additional clinical benefits not seen as before
4 August 2016 - The new indirect comparison is methodologically better but there is still no evidence of an additional ...
Posted by Michael Wonder on 03 Aug 2016
Ramucirumab in gastric cancer: no sign of an additional clinical benefit
1 August 2016 - Former orphan drug undergoes regular early benefit assessment; submitted studies unsuitable for assessment. ...
Posted by Michael Wonder on 03 Aug 2016
Nivolumab in advanced lung cancer: evidence for significant additional benefits
1 August 2016 - Advantages in overall survival and side effects. ...
Posted by Michael Wonder on 03 Aug 2016
Nivolumab in renal cell carcinoma: indication of additional clinical benefits
1 August 2016 - Benefits in overall survival, morbidity and side effects. ...
Posted by Michael Wonder on 02 Aug 2016
Afatinib dimaleate for patients with advanced squamous cell carcinoma of the lung: additional clinical benefits not there says IQWiG
1 August 2016 - Submitted comparisons for the benefit assessment are unsuitable. ...
Posted by Michael Wonder on 02 Aug 2016
Ospemifene in vulvovaginal atrophy: additional clinical benefits not seen says IQWiG
1 August 2016 - Incorrect study population, studies were too short. ...
Posted by Michael Wonder on 02 Jul 2016
Necitumumab in NSCLC: small additional benefit for patients with metastases
1 July 2016 - Survival advantage, but also disadvantages. ...
Posted by Michael Wonder on 02 Jul 2016
Ticagrelor prevention after myocardial infarction: little additional benefit
1 June 2016 - The IQWIG has re-examined the benefits of the use of ticagrelor (Brilique) after acute coronary syndrome. ...